Final program thematic sessions

Sunday, August 25th 
 Welcome Reception & Buffet

Monday, August 26th 
08.30 - 09.30  Registration + coffee
09.30 - 09.40
09.40 - 10.25
10.25 - 10.45
 Conference opening
 Opening by the Chair of the Organising Committee 
 Erik Frijlink, University of Groningen
 Recent developments in inhaled therapies for TB and other infectious diseases   
 Anthony Hickey, RTI
 Political involvement for TB     
 Anne Kuik, member of the House of Representatives, the Netherlands
10.45 - 11.15   Coffee break (exhibition)
11.20 - 11.55
11.55 - 12.30 
12.30 - 12.45
12.45 - 13.00
 Session 1: Formulations and devices
 Chair: Paolo Colombo, University of Parma
Formulation and device differences between animals and humans: Challenges for inhaled TB research 
 Pavan Muttil, University of New Mexico
 Multi-antimicrobial-drug compatible dry powder inhalers  
 Anne de Boer, University of Groningen
 Preliminary biopharmaceutical classification of antibiotic drugs for pulmonary delivery
 Sandrine Marchand, University of Poitiers (submitted abstract)
 High dose inhaled dry powder formulation of combination drugs for tuberculosis
 Shyamal Das, University of Otago (submitted abstract)
 13.00 - 14.00  Lunch break (exhibition)
 14.00 - 14.40
 Keynote lecture: Chemical synthesis of M. tuberculosis glycolipid antigens and their role in immune response
Adriaan Minnaard, University of Groningen
14.40 - 16.10

 Session 2: Anne de Boer award session
 Chair: Erik Frijlink, University of Groningen
On-stage presentation by early career researchers (submitted abstracts):
 1. Dynamic mucus-penetrating inhalable Micro-Particulate systems containing Host Defence peptides:
New therapeutic opportunity for Pulmonary TB
Rahul Verma, Institute of Nano Science and Technology
2. Formulating isoniazid for high dose dry powder inhalation
Imco Sibum, University of Groningen
3. Transient transfection of lung and airway epithelium with gamma interferon
Reena Bharti, CSIR-Central Drug Research Institute
4. Investigating Prophylactic Respiratory Delivery of Active Bacteriophage D29 to Protect against Inhaled
Mycobacterium tuberculosis H37Rv in Mice
Nicholas Carrigy, University of Alberta
5. A feasibility study of linezolid for pulmonary delivery
Mark van der Slijk, University of Groningen
6. Preparation and pharmacokinetic evaluation of a new antibiotic derivative for the potential treatment of
lung infections
Styliani Xiroudaki, University of Perugia
7. Dry powder administration of colistin via the Twincer®: an agreeable alternative to nebulization
Anne Akkerman, University Medical Center Groningen
8. Spray Drying Adjuvanted Tuberculosis Vaccine Encapsulates Nano-emulsions Within a Dry Powder Inhalable Product
Mellissa Gomez, University of Alberta
9. Softpellets for high dose pulmonary antibiotic therapy
Christian Etschmann, University of Kiel
10. Early Bactericidal Activity (EBA) of Colistin Sulphomethate Sodium Dry Powder Inhalation (DPI)
in Patients with Pulmonary Tuberculosis: a Proof-of Principle Randomized Trial
Antonia Saktiawati, Gadjah Mada University
11. Microparticles embedding streptomycin sulfate and isoniazid albumin co-nanoparticles for dry powder inhalers
Eride Quarta, University of Parma 
12. A Novel Intracellular Survival Mechanism of Mycobacterium tuberculosis
Jeffrey Buter, University of Groningen
16.10 - 16.30  Coffee break (exhibition)
16.30 - 17.05
17.05 - 17.40
17.40 - 18.00
18.00 - 18.15
18.15 - 18.30
 Session 3: Development and implementation
 Chair: Floris Grasmeijer, University of Groningen
 The quest for potentiators for antimicrobial drugs 
 Jurriaan de Steenwinkel, Erasmus Medical Centre Rotterdam
 Implementation of a new drug (regime) into a TB treatment guideline
 Dennis Falzon, WHO
 Development of a mycobacterial lung-orientated human infection model: first steps towards an inhaled BCG vaccine
 Keertan Dheda, University of Cape Town Lung Institute
 Development of inhaled pyrazinoic acid to treat tuberculosis
 Miriam Braunstein, University of North Carolina School of Medicine (submitted abstract) 
 A phase-1 clinical trial design for inhalable particles containing isoniazid and rifabutin
 Amit Misra, Central Drug Research Institute Lucknow (submitted abstract)  
18.30 - 18.40   Concluding remarks 
Tuesday, August 27th 
08.30 - 09.30  Coffee (exhibition)
09.30 - 09.35  Opening Erik
09.40 - 10.15
10.15 - 10.50
10.50 - 11.25
 Session 4:  Preclinical, models, and modelling - Part 1
 Chair: Rany Condos, New York University
 The power of in vitro models in the continuous battle against M. tuberculosis
 Tawanda Gumbo, Baylor Research Institute
 Pharmacokinetic modelling and inhalation of anti TB drugs
 Ulrika Simonsson, Uppsala University
 The role of Functional Respiratory Imaging (FRI) in TB treatment
 Wim Vos, OncoRadiomics
11.25 - 12.00  Coffee break (exhibition)
12.00 - 12.35
12.35 - 13.10
13.10 - 13.25
13.25 - 13.40
 Session 4: Preclinical, models, and modelling - Part 2
 Chair: Rany Condos, New York University

 The value of animal models in the development of inhaled TB therapies
 Lucila Garcia-Contreras, University of Oklahoma
 Inhaled therapies against NTM infections
 Jakko van Ingen, Radboud UMC
 PK/PD type modeling approach to support time-kill data interpretation of cefoxitin for the
 treatment of Mycobacterium abscessus 
 Julien Buyck, University of Poitiers (submitted abstract) 
 A novel antibiotic strategy for Mycobacterium tuberculosis based on high resolution microscopy
 of DNA condensation
 Nicole van der Wel, Amserdam University Medical Centre (submitted abstract
13.40 - 14.00  Lunch break (wrapped lunch to take on bus)
14.00 - 14.20  Bus to Beatrixoord: a state-of-the-art-tuberculosis treatment & care centre 
14.20 - 14.40
14.40 - 15.30
 Welcome in Beatrixoord: Huib Kerstjens
 Tour of the TB treatment and care centre 
15.30 - 16.10
16.10 - 16.45
 Session 5 (in Beatrixoord): Clinical trials and use - Part 1
 Chair: Edward Nardell, Harvard Medical School & Tjip van der Werf, Beatrixoord (UMCG)
 The pipeline of new TB drugs
 Andreas DiaconStellenbosch University
 The added value of pharmacokinetics and pharmacodynamics for old and repurposed TB drugs
 Simon Tiberi, Barts Health NHS Trust
16.45 - 17.00  Coffee break
17.00 - 17.35
17.35 - 18.10
 Session 5 (in Beatrixoord): Clinical trials and use - Part 2
 Chair: Edward Nardell, Harvard Medical School & Tjip van der Werf, Beatrixoord (UMCG)
 How to choose and evaluate a new treatment regimen for MDR-TB
 Martin Grobusch, Amsterdam Medical Center / University of Amsterdam
 The pros and cons of inhalation of new and current TB drugs
 Onno Akkerman, University Medical Center Groningen
18.10 - 18.30  Concluding remarks
18.45 - 19.00  Bus to dinner at Coendersborg
19.00 - 21.30  Dinner & Award ceremony
21.30  -22.00  Bus to Groningen